Located in the Frederick Innovative Technology Center, Inc., Veralox Therapeutics Inc is a small molecule drug discovery and development firm working on development of a first-in-class therapeutic targeting rare immune-mediated blood disorders. The effort is initially focused around heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT) both life-threatening diseases have a high mortality rate with limb amputations often required due to complications. Second generation therapeutic products are under development for type 1 diabetes (T1D) as well as other immune-mediated and inflammatory diseases.
